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Abstract
Aims/hypothesis Heterozygous activating mutations in the
pancreatic ATP-sensitive K+ channel cause permanent
neonatal diabetes mellitus (PNDM). This results from a
decrease in the ability of ATP to close the channel, which
thereby suppresses insulin secretion. PNDM mutations that
cause a severe reduction in ATP inhibition may produce
additional symptoms such as developmental delay and
epilepsy. We identified a heterozygous mutation (L164P) in
the pore-forming (Kir6.2) subunit of the channel in three
unrelated patients and examined its functional effects.
Methods The patients (currently aged 2, 8 and 20 years)
developed diabetes shortly after birth. The two younger
patients attempted transfer to sulfonylurea therapy but were
unsuccessful (up to 1.1 mg kg−1 day−1). They remain
insulin dependent. None of the patients displayed neuro-
logical symptoms. Functional properties of wild-type and
mutant channels were examined by electrophysiology in
Xenopus oocytes.
Results Heterozygous (het) and homozygous L164P KATP
channels showed a marked reduction in channel inhibition
by ATP. Consistent with its predicted location within the
pore, L164P enhanced the channel open state, which
explains the reduction in ATP sensitivity. HetL164P currents
exhibited greatly increased whole-cell currents that were
unaffected by sulfonylureas. This explains the inability of
sulfonylureas to ameliorate the diabetes of affected patients.
Conclusions/interpretation Our results provide the first
demonstration that mutations such as L164P, which
produce a severe reduction in ATP sensitivity, do not
inevitably cause developmental delay or neurological
problems. However, the neonatal diabetes of these patients
is unresponsive to sulfonylurea therapy. Functional analysis
of PNDM mutations can predict the sulfonylurea response.
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Introduction
ATP-sensitive potassium (KATP) channels link cellular
metabolism to membrane electrical activity by regulating
K+ fluxes across the plasma membrane [1]. They are found
in multiple tissues but are of particular importance in
regulating insulin secretion from pancreatic beta cells [1, 2].
At substimulatory glucose concentrations, KATP channels
are open so that the membrane potential is hyperpolarised
and Ca2+ influx and insulin secretion are prevented [3].
Glucose metabolism enhances ATP production, resulting in
closure of KATP channels, stimulation of electrical activity,
opening of voltage-gated Ca2+ channels and exocytosis of
insulin granules.
KATP channels are hetero-octamers of Kir6.x and
sulfonylurea receptor (SUR) subunits [4–6]. Four inwardly
rectifying subunits (Kir6.2 in pancreatic beta cells) form the
pore of the channel and four auxiliary SUR subunits (SUR1
in pancreatic beta cells) associate with the tetrameric pore
and regulate its gating [7–9]. Binding and/or hydrolysis of
Mg-nucleotides by the intracellular nucleotide-binding
domains (NBDs) of SUR produces channel opening [10–
13]. It is believed that reciprocal changes in the intracellular
concentrations of ATP and MgADP are involved in the
metabolic regulation of KATP channels.
Over the last 4 years, many different missense mutations
in the genes encoding Kir6.2 (KCNJ11) and SUR1
(ABCC8) have been shown to cause permanent neonatal
diabetes mellitus (PNDM). This is a rare disorder charac-
terised by high blood glucose levels that manifests within
the first 6 months of life. A subgroup of mutations were
associated with a more severe clinical profile characterised
by Delayed development of motor, intellectual and social
skills, muscle weakness, Epilepsy, facial dysmorphism and
Neonatal Diabetes (DEND syndrome) [14–16]. Mutations
in Kir6.2 have also been found to cause a remitting
relapsing form of neonatal diabetes that resembles transient
neonatal diabetes mellitus [17, 18].
All Kir6.2 mutations analysed to date were heterozygous
and most were de novo mutations [14, 19–21]. In most
cases, the diabetes they caused could be successfully treated
with sulfonylureas [14, 20, 22], which directly close KATP
channels by binding to the SUR1 subunit of the channel
[23]. All PNDM mutations result in a reduced KATP channel
sensitivity to inhibition by MgATP in vitro [15, 24]. This is
expected to cause an increased KATP current amplitude and
reduced insulin secretion. Studies to date suggest that the
severity of the clinical phenotype reflects the extent of the
reduction of the channel ATP sensitivity. Thus, mutations
that produce a small increase in KATP current in the
presence of physiological concentrations of MgATP (1–
5 mmol/l) lead to PNDM, whereas mutations that cause a
larger increase in KATP current give rise to DEND
syndrome [15].
In this paper, we identify a KCNJ11 mutation (L164P)
that causes neonatal diabetes without obvious neurological
complications. In functional studies, we show that the
L164P mutation produces a large increase in the resting
whole-cell current and a marked reduction in KATP channel
sensitivity to inhibition by ATP. These effects are a
secondary consequence of an increase in the channel open
probability (Po) produced by the mutation. Surprisingly,
other mutations that produce a similar increase in Po cause
DEND syndrome. The L164P mutant channel was also far
less blocked by the sulfonylurea tolbutamide, which
explains why the patients were unable to transfer to
glibenclamide therapy.
Methods
Participants Informed consent was obtained from all
individuals investigated (or from their parents if they were
children).
Molecular genetic analysis Genomic DNA was extracted
from peripheral lymphocytes using standard procedures.
The KCNJ11 gene was amplified and sequenced as
described [25]. Other family members were also tested for
the novel mutation. Family relationships were confirmed
using a combination of six microsatellites on chromosome
11: D11S902, D11S419, D11S1397, D11S1901, D11S921
and D11S1888.
Oocyte preparation Female Xenopus laevis were anaesthe-
tised with ethyl 3-aminobenzoate methanesulfonate salt
(MS222; 2 g/l added to the water). One ovary was removed
via a mini-laparotomy, the incision sutured and the animal
allowed to recover. Subsequently, animals were operated on
for a second time, but under terminal anaesthesia. Immature
stage V–VI oocytes were incubated for 60 min with 1 mg/
ml collagenase (Type V; Sigma, Poole, UK) and manually
defolliculated. All procedures were carried out in accor-
dance with UK Home Office Legislations and the Univer-
sity of Oxford ethical guidelines. Oocytes were coinjected
with ∼0.8 ng wild-type or mutant Kir6.2 mRNA and ∼4 ng
mRNA encoding SUR. The final injection volume was
50 nl per oocyte. Isolated oocytes were maintained in
Barth’s solution and studied 1–4 days after injection.
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Electrophysiology Wild-type or mutant Kir6.2 (GenBank
D50581) were coexpressed with SUR1 in Xenopus oocytes
(GenBank L40624) as described [26]. Because all the
patients were heterozygous for the L164P mutation, their
pancreatic beta cells will contain a mixture of wild-type and
mutant Kir6.2 subunits. To simulate this heterozygosity, we
coinjected Xenopus oocytes with a 1:1 mixture of mutant
and wild-type Kir6.2 together with SUR1 mRNA. This is
expected to give rise to a mixed population of channels
composed of homomeric wild-type channels, homomeric
mutant channels and heteromeric channels containing
between one and three mutant subunits [21]. We refer to
this global channel population as heterozygous channels.
Whole-cell currents were recorded using a two-electrode
voltage clamp in response to voltage steps of ±20 mV from
a holding potential of −10 mV, filtered at 1 kHz and
digitised at 4 kHz. Oocytes were perfused with a solution
containing (in mmol/l): 90 KCl, 1 MgCl2, 1.8 CaCl2 and
5 HEPES (pH 7.4 with KOH). Metabolic inhibition was
produced by 3 mmol/l sodium azide.
Macroscopic currents were recorded from giant inside-out
patches using an EPC10 amplifier (List Medical Electronics,
Darmstadt, Germany) controlled with Pulse v8.74 software
(Heka Electronik, Lambrecht, Germany). Macroscopic cur-
rents were elicited by 3 s voltage ramps from −110 to
+100 mV (holding potential 0 mV), or recorded at a constant
potential of −60 mV. They were filtered at 0.5 kHz and
digitised at 1 kHz. The pipette solution contained (mmol/l):
140 KCl, 1.2 MgCl2, 2.6 CaCl2, 10 HEPES (pH 7.4 with
KOH). The internal (bath) solution contained (mmol/l):
107 KCl, 1 K2SO4, 2 MgCl2, 10 EGTA, 10 HEPES (pH 7.2
with KOH) and Mg-nucleotides as indicated. Experiments
were conducted at 20–22°C. Solutions were changed using
a local perfusion system consisting of tubes of 200 μm
diameter into which the tip of the patch pipette was
inserted.
Nucleotide concentration–inhibition curves were fit with
the Hill equation:
G
Gc
¼ 1
1þ ATP½ =IC50ð Þh
where G is the KATP conductance in the presence of ATP,
Gc is the KATP conductance in the absence of the
nucleotide, [ATP] is the ATP concentration, IC50 is the
nucleotide concentration at which inhibition is half maxi-
mal and h is the slope factor (Hill coefficient).
Single-channel currents were measured at −60mV, filtered
at 5 kHz and digitised at 20 kHz. Unitary amplitude and Po
were measured from the Gaussian fit to all-points amplitude
histograms of tracts of current of 30–90 s duration.
Data were analysed with in-house routines developed in
the IgorPro platform (Wavematrics, Portland, OR, USA).
Data are given as means±SEM in the text and in the
figures. Statistical significance was evaluated using a two-
tailed Student t test and p<0.05 taken to indicate a
significant difference.
Results
Patient characteristics and genetics Three unrelated pro-
bands with permanent neonatal diabetes were shown to be
heterozygous for the KCNJ11 gene mutation L164P
(c.491T>C, p.Leu164Pro). All were female and had unaf-
fected parents of different ethnic origin. Two patients have
been reported previously [27, 28]. Mutation testing and
microsatellite analysis of DNA from both parents and the
child for two of the cases confirmed that the mutation had
arisen de novo (the parents of the third case were not
available for testing). None of the patients had any
neurological complications or obvious developmental delay.
The first patient is currently 8 years old. She was born in
Singapore from Sri Lankan parents, at 38 weeks of
gestation with a birthweight of 2.6 kg. She developed
diabetes at 30 weeks of age. When she came to Australia at
the age of 6.5 years, her HbA1c level was elevated (7.4%)
and her diabetes required insulin treatment (0.45 U kg−1
day−1). Glibenclamide treatment (1.0 mg kg−1 day−1) was
trialled for 2 months (at 7 years of age) but did not produce
a decrease in her insulin requirement. She continues to
require insulin (up to 0.7 U kg−1 day−1) with an HbA1c
ranging from 7.2 to 8.2%. She has normal developmental
milestones, her neurological examination is normal and she
has no evidence of diabetic complications.
The second patient, born in Australia of Afghan origin, is
currently 2.7 years old. She was born at term following an
uneventful pregnancy, with a birthweight of 2.7 kg. She
presented at 8 weeks in diabetic ketoacidosis and was
subsequently treated (at 2.5 months for 4 weeks, then at
5 months for 3 months) with glibenclamide (up to 1.1 mg
kg−1 day−1, regimens of two times per day or three times per
day), but had no reduction in insulin requirement (0.4 U
kg−1 day−1) [28]. Her mean HbA1c since diagnosis has been
7.6% (range 7.2–8.7%). Assessment at 5 months by a
neurologist was entirely normal, with a normal EEG.
Subsequently, she has had normal developmental milestones
and her neurological examinations have been normal at all
follow up visits every 3 months. Diabetic complications
have not been assessed due to the young age of the patient.
The third patient is from Slovakia [27]. She was born at
term with a birthweight of 2.6 kg, and was diagnosed with
diabetes at 5 weeks of age. She is currently 20 years old and
is treated with insulin (1.24 U kg−1 day−1). Glibenclamide
transfer was not attempted because the patient also suffers
from hepatitis C. She has poor glycaemic control, with an
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HbA1c level of 15.2%, and various diabetic complications
including retinopathy and nephropathy. Psychomotoric
development in childhood was normal. A neurological
examination suggested the presence of diabetic motoric
polyneuropathy in the lower extremities but there were no
further neurological findings. Although her IQ was not
tested, she successfully completed a specialised business
school training suggesting normal mental development.
Functional analysis: effects on whole-cell KATP currents We
examined the functional effects of the L164P mutation by
heterologous expression in Xenopus oocytes. When wild-
type Kir6.2/SUR1 channels are expressed in oocytes they
are normally closed because they are inhibited by resting
intracellular ATP concentrations ([ATP]i). They can be
opened, however, by azide (3 mmol/l; Fig. 1), a metabolic
inhibitor that lowers [ATP]i [29]. Heterozygous L164P
(hetL164P) currents were about 18-fold larger at rest than
wild-type currents, but increased twofold on metabolic
inhibition indicating that the channel is only partially closed
at resting ATP levels (Fig. 1). In contrast, homomeric
L164P (homL164P) channels displayed a much greater
resting current and were little affected by metabolic
inhibition (Fig. 1).
The sulfonylurea tolbutamide (0.5 mmol/l) blocked
whole-cell KATP currents by 98% but had no effect on
homL164P currents (4% block). HetL164P channels were
blocked by only 54% (Fig. 1).
Functional analysis: effects on KATP channel ATP
sensitivity The increase in resting whole-cell KATP currents
suggests that the L164P mutation may reduce the channel
ATP sensitivity, as found for other PNDM mutations [21].
We first measured the ATP sensitivity of wild-type and
mutant KATP currents in the absence of Mg
2+, to isolate the
effects of ATP on Kir6.2 (in the absence of Mg2+, ATP does
not interact with SUR1 [11]). Both homL164P and
hetL164P channels had severely impaired ATP sensitivity.
HomL164P channels were not blocked at all by ATP, even
at concentrations as high as 10 mmol/l. The concentration–
inhibition curve for hetL164P showed a striking shift to
higher ATP concentrations, with an IC50 of about 100 μmol/l,
and a marked pedestal of unblocked current at very high
ATP concentrations. The data were best fitted by assuming
that in the heterozygous state about 20% of channels are
never closed by ATP (Fig. 2a,b and Table 1).
Molecular mechanism of the reduced ATP sensitivity Mu-
tations that reduce the ATP sensitivity of the KATP channel
can act in several ways. They may prevent ATP binding
directly. They may impair the mechanism by which
nucleotide binding is coupled to channel gating. They
may also stabilise the intrinsic open state of the channel (i.e.
that in the absence of ATP), which shifts the gating
equilibrium in the presence of ATP towards channel
opening and thus indirectly reduces the channel ATP
sensitivity (e.g. [15, 30, 31]).
In a structural model of Kir6.2 [32], L164P lies within
the channel pore, at a considerable distance from the ATP-
binding site (Fig. 3). It is not predicted to interact directly with
ATP. We therefore examined whether the L164P mutation
alters intrinsic gating. Experiments were carried out in the
absence of ATP, where intrinsic gating can be assessed. The
L164P mutation had no effect on single-channel current
amplitude (Table 2). However, the intrinsic Po was markedly
increased, being 0.86 (n=6) for homL164P compared with
0.4 (n=4) for wild-type channels (Fig. 4 and Table 2). This
suggests that, at least in part, the L164P mutation alters
channel ATP sensitivity indirectly, via an increase in Po.
Effects on KATP channel ATP sensitivity in the presence of
Mg2+ Previous studies have shown that Kir6.2 mutations
associated with neonatal diabetes may not only decrease the
sensitivity of Kir6.2 to ATP, but can also enhance channel
activation by Mg-nucleotides [24]. We therefore explored
the effect of the L164P mutation on the ATP sensitivity in
the presence of 2 mmol/l Mg2+.
Surprisingly, there was no difference in the effect of ATP
in the presence and absence of Mg2+ on homL164P channels
(Fig. 2c,d). This contrasts with what has been observed for
mutations in the ATP-binding site that completely abolished
ATP inhibition in the absence of Mg2+, such as R50P and
G334D: channels containing these mutations were activated
by MgATP [33, 34]. The IC50 for ATP inhibition of
hetL164P channels was also not significantly affected by
Mg2+, although the pedestal of unblocked current at high
Fig. 1 Whole-cell KATP current. Mean steady state whole-cell
currents evoked by voltage steps from −10 to −30 mV before (control,
white bars) and after application of 3 mmol/l azide (grey bars) and in
the presence of 3 mmol/l azide plus 0.5 mmol/l tolbutamide (black
bars). The number of oocytes was five to seven in each case. G, KATP
conductance; Gc, KATP conductance expressed relative to the
conductance in the absence of the nucleotide. WT, wild-type;
hetL164P and homL164P channels as indicated
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ATP concentrations was increased by about 50% (Table 1). At
3 mmol/l MgATP, a concentration within the physiological
range, the unblocked current was 34%, substantially greater
than that found for wild-type channels (<1%; Table 1).
Functional analysis: effects on MgADP sensitivity The lack
of MgATP activation of hetL164P channels could be due to
reduced functional coupling between SUR1 and Kir6.2-
L164P, or to reduced MgATP binding/hydrolysis at the
Table 1 ATP sensitivity of wild-type and mutant channels
IC50 (Mg-free) h (Mg-free) IC50 (2 mmol/l Mg
2+) h (2 mmol/l Mg2+) A (2 mmol/l Mg2+) %Imax (3 mmol/l MgATP)
Wild-type 9.6±1.6 1.30±0.08 15.8±3.0 0.99±0.05 n.a. 0.01±0.01
hetL164P 100±8* 1.10±0.05 118±29* 1.16±0.34 0.29±0.07* 33.6±3.4*
homL164P n.a. n.a. n.a. n.a. n.a. 98±1*
Values are means±SEM. The number of patches was four to nine in each case.
AThe fraction of unblocked current used to fit the ATP concentration–inhibition relationship; h Hill coefficient; IC50, ATP concentration (μmol/l)
producing half-maximal inhibition; %Imax the per cent unblocked current in the presence of 3 mmol/l MgATP; n.a. not applicable (as no block).
*p<0.05 vs wild-type
Fig. 2 ATP-inhibition of L164P channels is less that that of wild-type
channels. a, c Currents recorded in inside-out patches excised from
Xenopus oocytes expressing hetKir6.2-L164P/SUR1 (hetL164P) or
homKir6.2-L164P/SUR1 (homL164P) channels, as indicated, in
response to 3 s voltage ramps from −110 to +100 mV. ATP
(10 mmol/l) was applied as indicated by the horizontal bars in the
absence (a) or presence (c) of 2 mmol/l Mg2+. b, d, mean relationship
between [ATP] and KATP conductance (G), expressed relative to the
conductance in the absence of the nucleotide (Gc), for wild-type (white
circles, n=9), hetL164P (white/black circles, n=6) or homL164P
(black circles, n=4) channels. Experiments were carried out in the
absence (b) or presence (d) of 2 mmol/l Mg2+. The continuous lines
through the black circles were drawn by eye. The smooth curves are
the best fit to the Hill equation with IC50 of 11 μmol/l (wild-type) and
100 μmol/l (hetL164P) (b, 0 mmol/l Mg2+) or IC50 of 16 μmol/l (wild-
type) and 122 μmol/l (hetL164P) (d, 2 mmol/l Mg2+)
806 Diabetologia (2008) 51:802–810
NBDs of SUR1. To explore the former possibility, we
measured the ability of MgADP to activate hetL164P
channels preblocked by 100 μmol/l MgATP. It was
necessary to preblock the channels as the mutant channel
has an open probability close to maximal and further
activation is therefore not possible. Figure 5 shows that
30 μmol/l MgADP activates wild-type currents by 3.7±
1.8 fold (n=3) and that 100 μmol/l MgADP did not
produce any further increase (3.7±1.2-fold, n=3). In
contrast, hetL164P channels were activated less: 1.4±0.1
fold (n=3) by 30 μmol/l MgADP and 1.5±0.1 fold (n=4)
by 100 μmol/l MgADP.
Despite the fact that 100 μmol/l MgATP blocked mutant
channels less, the lower extent of activation of hetL164P
channels by 30 μmol/l MgADP is not due to the fact that
channel activity is already maximal, as the amplitude is still
significantly less than that in control solution (Fig. 5).
Discussion
We describe the clinical and functional effects of a KCNJ11
mutation, L164P, associated with permanent neonatal
diabetes. This mutation causes a marked reduction in KATP
channel inhibition by ATP primarily by stabilising the open
state of the channel. This leads to an increase in the whole-
cell KATP current, and in beta cells is expected to result in a
reduction in insulin secretion. Surprisingly, unlike other
mutations that reduced the channel ATP sensitivity by a
similar amount, no motor or mental developmental delay
was associated with the L164P mutation.
Structural considerations and molecular basis for reduced
ATP sensitivity In a homology model of Kir6.2 [32], L164
lies partway along the permeation pathway, 35 Å away
from the ATP-binding site (Fig. 3). It is therefore unlikely
that it acts by reducing ATP binding directly. The side-
chains of L164 point into the pore, forming a hydrophobic
girdle that is narrow enough to prevent the passage of water
and hydrated K+ ions [35], which suggests that L164 may
form a hydrophobic gate within the pore. Functional studies
support this idea. Following mutation of L164 to cysteine,
cadmium ions were able to block the KATP channel with
high affinity [36, 37], suggesting that the four cysteines
(one on each subunit) come together close enough to form a
high-affinity binding site for Cd2+. These data indicate that
the side-chain of L164 must face into the pore, and that the
pore is very narrow at this position. Substitution of a
proline for L164 is expected to produce a kink in the α-
helix [38] and disrupt the hydrophobic gate. It is therefore
not surprising that the L164P mutation caused a dramatic
effect on the Po. Mutation of L164 to cysteine, alanine,
valine, threonine or glycine also produces a very large
increase in Po [30, 36, 37, 39], consistent with the
importance of this residue in channel gating.
The fact that the L164P mutation enhanced Po can
explain, in part, the reduced ATP sensitivity of the channel.
It is also possible that the mutation may have effects
additional to stabilisation of the channel open state.
Fig. 3 Homology model of Kir6.2 [32]. For clarity, only two subunits
are shown. ATP (yellow) is shown in its binding site. Residue L164 is
shown in red
Table 2 Single-channel parameters for wild-type and homL164P
channels
Po i (pA)
Wild-type 0.39±0.05 4.0±0.1
homL164P 0.86±0.01* 4.1±0.1
Mean±SEM values of intrinsic open probability (Po) and single-
channel current (i) measured at −60 mV
The number of patches was five to six in each case
* p<0.05 vs wild-type
Fig. 4 The L164P mutation enhances single-channel activity. Repre-
sentative single KATP channel currents recorded at −60 mV in inside-
out patches from oocytes expressing wild-type or homL164P channels,
as indicated. Currents were recorded in the absence of Mg2+ and
nucleotides
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Effect of Mg2+ on Kir6.2-L164P/SUR1 channel ATP
sensitivity In contrast to all PNDM mutations studied to
date [24], MgATP was unable to enhance the activity of
either homL164P or hetL164P channels. The lack of MgATP
activation of homL164P channels may be due to the fact
that Po is already very high and thus there is no scope for
further activation. However, little MgATP activation was
also observed for hetL164P channels. This is in marked
contrast to other mutations that caused enhanced Po (I296L,
[16], V59G [15]) where MgATP activated both homomeric
and heterozygous channels. It is therefore possible that the
L164P mutation reduces the efficacy of coupling between
SUR1 and Kir6.2, and thereby decreases the ability of
MgATP to stimulate channel activity. In support of this idea,
MgADP activation of hetL164P channels was also reduced.
This may explain the inability of Mg2+ to reduce ATP
inhibition of hetL164P channels, since it is well established
that MgATP must be hydrolysed to MgADP to stimulate
channel activity.
The reason for the lack of Mg-nucleotide activation of
hetL164P channels is unclear. Because L164 lies within the
pore, far away from the NBDs of SUR1, the effect must be
mediated allosterically. It is possible that this is mediated by
an interaction between the backbone of L164 itself, or
transmembrane domain 2 (within which L164 lies), and the
transmembrane domains of SUR1. In the absence of an
atomic resolution structure of the KATP channel complex,
however, this cannot be definitely determined.
HomL164P channels were not blocked by tolbutamide,
as expected because of their high Po [40]. The lower
efficacy of tolbutamide on hetL164P channels (about 50%
block) may reflect the enhanced Po of channels within the
heterozygous population containing mutant subunits. It
could also reflect impaired coupling between SUR1 and
Kir6.2, such as that found for MgADP.
Clinical implications Previous studies of KCNJ11 muta-
tions have suggested that there is a good correlation
between the percentage of current that remains unblocked
in the presence of 3 mmol/l MgATP and the clinical
phenotype. Namely, currents that are >30% of maximal are
Fig. 5 Sensitivity to MgADP of wild-type and hetL164P channels. a
Representative currents (I) recorded at −60 mV from inside-out
excised membrane patches from Xenopus oocytes expressing wild-
type or hetL164P channels, as indicated. Patches were exposed to
100 μmol/l ADP in the continuous presence of 100 μmol/l ATP:
2 mmol/l Mg2+ was present throughout. b Mean current in the
presence of 100 μmol/l MgATP or 30 or 100 μmol/l MgADP plus
100 μmol/l MgATP, normalised to the current in the absence of
nucleotides for wild-type (grey bars) and hetL164P (black bars)
channels. Bars indicate means±SEM. The number of patches was
three to four in each case
Fig. 6 Mean KATP current (expressed as a % of maximum) measured
in the presence of 3 mmol/l MgATP from inside-out patches
expressing heterozygous mutant channels as indicated. The dashed
line indicates the maximal current amplitude normally associated with
PNDM. iDEND, intermediate DEND syndrome (i.e. neonatal diabetes
with developmental delay [21]). Data for wild-type (WT) and Kir6.2-
R201H channels are from [14], for Y330C and F333I from [26], for
Q52R, V59G and R201C from [15], for V59M from [24], for I296L
from [16] and for G334D from [34]
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associated with DEND syndrome, and those that lie
between 5–10% of maximal with neonatal diabetes alone,
compared with a current of <1% for wild-type channels
(Fig. 6). The L164P mutation does not conform to this
simple relationship between the functional effects of the
mutation and the clinical phenotype. The magnitude of the
hetL164P current in 3 mmol/l MgATP was 36%, yet none
of the patients had extra-pancreatic symptoms.
The reason for this anomaly is not clear, particularly as
the resting whole-cell current was also very large. Previous
studies have also indicated that such large whole-cell
currents are invariably associated with more severe clinical
symptoms. The lack of responsiveness of the patient to
sulfonylureas is consistent with the very large increase in
Po and the resting whole-cell current. It is therefore likely
that hetL164P channels expressed in Xenopus oocytes are a
reasonable model for the pancreatic beta cell KATP channels
of the patients. We are therefore forced to conclude that
compensatory mechanisms must ameliorate the extra-
pancreatic effects of this mutation. The fact that the patients
had very different ethnic origins suggests the compensatory
mechanism is unlikely to reflect a shared genetic back-
ground: however, it does appear to be specific to the L164P
mutation, which is unique (to date) in having a marked
functional effect in vitro despite causing neonatal diabetes
without neurological complications.
Importantly, a maximally effective concentration of
tolbutamide only blocked hetL164P channels by 50%. All
patients to date whose channels are blocked by <65% have
not been able to transfer from insulin treatment to sulfonyl-
urea therapy. This suggested that our patients would be
unable to transfer to sulfonylurea therapy, as indeed was
found to be the case. This is likely to be due to the fact that
L164P destabilises the long closed state of the channel, to
which sulfonylureas preferentially bind, and which is rarely
entered in channels with enhanced Po. Our results further
suggest that not all patients with permanent neonatal dia-
betes will necessarily respond to sulfonylurea treatment, and
indicates that knowledge of the functional effect of the mu-
tation is helpful for predicting the drug response in patients.
Acknowledgements We thank the patients and their referring
clinicians. Financial support was provided by the Wellcome Trust (F.
M. Ashcroft, A. T. Hattersley), the Royal Society (F. M. Ashcroft), the
European Union (Integrated Project EuroDia LSHM-CT-2006–518153
in the Framework Programme 6 [FP6]) of the European-Community
(F. M. Ashcroft, A. T. Hattersley), the Sir Graham Wilkins studentship
(S. E. Flanagan) and research grants from the Slovak Research and
Development Agency (51–014205; I. Klimes) and Slovak Ministry of
Health (MZ.2005/15-NEDU-01; I. Klimes). P. Tammaro holds a
Junior Research Fellowship at the Wolfson College, B. Zadek holds an
OXION scholarship, A. T. Hattersley is a Wellcome Trust Research
Leave Fellow and F. M. Ashcroft is a Royal Society Research
Professor.
Duality of interest The authors declare that there is no duality of
interest associated with this manuscript.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Seino S, Miki T (2003) Physiological and pathophysiological roles
of ATP-sensitive K+ channels. Prog Biophys Mol Biol 81:133–176
2. Ashcroft FM, Harrison DE, Ashcroft SJ (1984) Glucose induces
closure of single potassium channels in isolated rat pancreatic
beta-cells. Nature 312:446–448
3. Ashcroft F, Rorsman P (2004) Type 2 diabetes mellitus: not quite
exciting enough? Hum Mol Genet 13(Spec No. 1):R21–R31
4. Inagaki N, Gonoi T, Clement JPT et al (1995) Reconstitution of
IKATP: an inward rectifier subunit plus the sulfonylurea receptor.
Science 270:1166–1170
5. Clement JPT, Kunjilwar K, Gonzalez G et al (1997) Association
and stoichiometry of KATP channel subunits. Neuron 18:827–838
6. Shyng S, Nichols CG (1997) Octameric stoichiometry of the KATP
channel complex. J Gen Physiol 110:655–664
7. Tucker SJ, Gribble FM, Zhao C, Trapp S, Ashcroft FM (1997)
Truncation of Kir6.2 produces ATP-sensitive K+ channels in the
absence of the sulphonylurea receptor. Nature 387:179–183
8. Drain P, Li L,Wang J (1998) KATP channel inhibition by ATP requires
distinct functional domains of the cytoplasmic C terminus of the
pore-forming subunit. Proc Natl Acad Sci U S A 95:13953–13958
9. Haider S, Tarasov AI, Craig TJ, Sansom MS, Ashcroft FM (2007)
Identification of the PIP(2)-binding site on Kir6.2 by molecular
modelling and functional analysis. EMBO J 26:3749–3759
10. Nichols CG, Shyng SL, Nestorowicz A et al (1996) Adenosine
diphosphate as an intracellular regulator of insulin secretion.
Science 272:1785–1787
11. Gribble FM, Tucker SJ, Ashcroft FM (1997) The essential role of
the Walker A motifs of SUR1 in KATP channel activation by Mg-
ADP and diazoxide. EMBO J 16:1145–1152
12. Shyng S, Ferrigni T, Nichols CG (1997) Regulation of KATP
channel activity by diazoxide and MgADP. Distinct functions of
the two nucleotide binding folds of the sulfonylurea receptor. J
Gen Physiol 110:643–654
13. Zingman LV, Alekseev AE, Bienengraeber M et al (2001) Signaling
in channel/enzyme multimers: ATPase transitions in SUR module
gate ATP-sensitive K+ conductance. Neuron 31:233–245
14. Gloyn AL, Pearson ER, Antcliff JF et al (2004) Activating
mutations in the gene encoding the ATP-sensitive potassium-
channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J
Med 350:1838–1849
15. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft
FM (2004) Molecular basis of Kir6.2 mutations associated with
neonatal diabetes or neonatal diabetes plus neurological features.
Proc Natl Acad Sci U S A 101:17539–17544
16. Proks P, Girard C, Haider S et al (2005) A gating mutation at the
internal mouth of the Kir6.2 pore is associated with DEND
syndrome. EMBO Rep 6:470–475
17. Flanagan SE, Patch AM, Mackay DJ et al (2007) Mutations in
ATP-sensitive K+ channel genes cause transient neonatal diabetes
and permanent diabetes in childhood or adulthood. Diabetes
56:1930–1937
Diabetologia (2008) 51:802–810 809
18. Gloyn AL, Reimann F, Girard C et al (2005) Relapsing diabetes
can result from moderately activating mutations in KCNJ11. Hum
Mol Genet 14:925–934
19. Massa O, Iafusco D, D, Amato E et al (2005) KCNJ11 activating
mutations in Italian patients with permanent neonatal diabetes.
Hum Mutat 25:22–27
20. Sagen JV, Raeder H, Hathout E et al (2004) Permanent neonatal
diabetes due to mutations in KCNJ11 encoding Kir6.2: patient
characteristics and initial response to sulfonylurea therapy.
Diabetes 53:2713–2718
21. Ashcroft FM (2005) ATP-sensitive potassium channelopathies:
focus on insulin secretion. J Clin Invest 115:2047–2058
22. Zung A, Glaser B, Nimri R, Zadik Z (2004) Glibenclamide
treatment in permanent neonatal diabetes mellitus due to an
activating mutation in Kir6.2. J Clin Endocrinol Metab 89:5504–
5507
23. Gribble FM, Reimann F (2003) Sulphonylurea action revisited:
the post-cloning era. Diabetologia 46:875–891
24. Proks P, Girard C, Ashcroft FM (2005) Functional effects of
KCNJ11 mutations causing neonatal diabetes: enhanced activation
by MgATP. Hum Mol Genet 14:2717–2726
25. Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT
(2006) Mutations in KCNJ11, which encodes Kir6.2, are a
common cause of diabetes diagnosed in the first 6 months of life,
with the phenotype determined by genotype. Diabetologia 49:
1190–1197
26. Tammaro P, Girard C, Molnes J, Njolstad PR, Ashcroft FM (2005)
Kir6.2 mutations causing neonatal diabetes provide new insights
into Kir6.2-SUR1 interactions. EMBO J 24:2318–2330
27. Stanik J, Gasperikova D, Paskova M et al (2007) Prevalence of
permanent neonatal diabetes in Slovakia and successful replace-
ment of insulin with sulfonylurea therapy in KCNJ11 and ABCC8
mutation carriers. J Clin Endocrinol Metab 92:1276–1282
28. Pearson ER, Flechtner I, Njolstad PR et al (2006) Switching from
insulin to oral sulfonylureas in patients with diabetes due to Kir6.2
mutations. N Engl J Med 355:467–477
29. Gribble FM, Ashfield R, Ammala C, Ashcroft FM (1997)
Properties of cloned ATP-sensitive K+ currents expressed in
Xenopus oocytes. J Physiol 498:87–98
30. Enkvetchakul D, Loussouarn G, Makhina E, Shyng SL, Nichols CG
(2000) The kinetic and physical basis of KATP channel gating:
toward a unified molecular understanding. Biophys J 78:2334–2348
31. Trapp S, Proks P, Tucker SJ, Ashcroft FM (1998) Molecular
analysis of ATP-sensitive K channel gating and implications for
channel inhibition by ATP. J Gen Physiol 112:333–349
32. Antcliff JF, Haider S, Proks P, Sansom MS, Ashcroft FM (2005)
Functional analysis of a structural model of the ATP-binding site
of the KATP channel Kir6.2 subunit. EMBO J 24:229–239
33. Shimomura K, Girard CA, Proks P et al (2006) Mutations at the
same residue (R50) of Kir6.2 (KCNJ11) that cause neonatal diabetes
produce different functional effects. Diabetes 55:1705–1712
34. Masia R, Koster JC, Tumini S et al (2007) An ATP-binding
mutation (G334D) in KCNJ11 is associated with a sulfonylurea-
insensitive form of developmental delay, epilepsy, and neonatal
diabetes. Diabetes 56:328–336
35. Haider S, Antcliff JF, Proks P, Sansom MS, Ashcroft FM (2005)
Focus on Kir6.2: a key component of the ATP-sensitive potassium
channel. J Mol Cell Cardiol 38:927–936
36. Loussouarn G, Makhina EN, Rose T, Nichols CG (2000) Structure
and dynamics of the pore of inwardly rectifying KATP channels. J
Biol Chem 275:1137–1144
37. Loussouarn G, Phillips LR, Masia R, Rose T, Nichols CG (2001)
Flexibility of the Kir6.2 inward rectifier K+ channel pore. Proc
Natl Acad Sci U S A 98:4227–4232
38. Cordes FS, Bright JN, Sansom MS (2002) Proline-induced
distortions of transmembrane helices. J Mol Biol 323:951–960
39. Enkvetchakul D, Loussouarn G, Makhina E, Nichols CG (2001)
ATP interaction with the open state of the KATP channel. Biophys
J 80:719–728
40. Reimann F, Tucker SJ, Proks P, Ashcroft FM (1999) Involvement
of the n-terminus of Kir6.2 in coupling to the sulphonylurea
receptor. J Physiol 518:325–336
810 Diabetologia (2008) 51:802–810
